Verastem

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verastem (VSTM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy?

Verastem Oncology: An Undervalued KRAS Oncology Play

Amgen

Amneal Pharmaceuticals

Mirati Therapeutics

Viking Therapeutics

Healthcare bargain hunters can find good values in quality low-priced stocks.

Top Drug Stocks Under $5

Is  (VSTM) Outperforming Other Medical Stocks This Year?

Has Verastem (VSTM) Outpaced Other Medical Stocks This Year?

Verastem has been struggling lately, but the selling pressure may be coming to an end soon.

Verastem Sees Hammer Chart Pattern: Time to Buy?

As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM).

Verastem, Inc. (VSTM) Shares March Higher, Can It Continue?

Verastem: Outlook For 2020-21

Verastem: Still Bullish After Chugai Pharmaceutical Deal

Billionaire investor Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed earlier this week his firm established a new 14.91% stake in Verastem Inc.

Steven Cohen Renews His Interest in Verastem

Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.

Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

Implied Volatility Surging for Verastem (VSTM) Stock Options

Verastem: Earnings Beat And Executing 6-2-5 Plan Trigger Unjustified Sell-Off

Verastem, Inc. (VSTM) CEO Brian Stuglik on Q3 2019 Results - Earnings Call Transcript

Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates

Verastem Oncology's share price continues to flatline as we approach the end of 2019. The market appears to have branded COPIKTRA's launch as a dud.

Verastem: Uncovering Bullish Signals

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

Verastem, Inc. (VSTM) CEO Brian Stuglik on Q2 2019 Results - Earnings Call Transcript

Verastem (VSTM) delivered earnings and revenue surprises of 2.04% and 41.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Verastem (VSTM) Reports Q2 Loss, Tops Revenue Estimates

Verastem announced they out-licensed COPIKTRA to Sanofi Develop and Commercialize in emerging markets. Verastem will receive an upfront payment of $5M, plus milestones and royalties.

Verastem Licenses COPIKTRA To Sanofi Ahead Of Critical Q2 Earnings

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

Verastem Up on Positive Data From Early-Stage Copiktra Study

Verastem Oncology presented COPIKTRA data showing response rates of 44% to 57%, including complete response rates of 15% to 22% in patients with relapsed or refractory peripheral T-cell lymphoma.

Verastem Shares Response Rate From COPIKTRA Data

Blueprint Medicines

Incyte

uniQure

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

Verastem recently reported an uninspiring earnings report that revealed a big miss on revenue. The share price was decimated in the subsequent trading day and has me contemplating my position.

Verastem: A Speculative Buy

Verastem, Inc. (VSTM) CEO Robert Forrester on Q1 2019 Results - Earnings Call Transcript

Verastem (VSTM) delivered earnings and revenue surprises of -10.87% and -41.16%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Verastem Stock (VSTM)